Jazz Pharmaceuticals PLC (JAZZ) Stock AnalysisJAZZStock AnalysisJazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Jazz Pharmaceuticals appears to be a good buy right now due to its strong growth potential driven by the recent FDA approval of Ziihera, which has increased peak sales forecasts to $3B-$5B. The current price of $244.54 is well below the average analyst price target of $299, suggesting significant upside potential. Additionally, the company's gross margin has improved to 76.30% in Q2 2026, indicating strong profitability. However, the main risk is the negative earnings per share of -1.52 in Q1 2025, which highlights past volatility in earnings.

21 analysts cover JAZZ: 16 rate it Buy, 5 Hold and 0 Sell. The average price target is 218.92.